



European Hematology Association

EHA2022 Congress

Messe Wien Exhibition &
Congress Center and Online
Vienna, Austria

June 9-17, 2022



Friday, June 10

Poster Session

16:30–17:45 CEST

Hall D

Gemtuzumab Ozogamicin

P579

A PHASE 4 STUDY OF FRACTIONATED GEMTUZUMAB OZOGAMICIN ON QT INTERVAL AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA

Montesinos P



Bosutinib

P717

BOSUTINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: GASTROINTESTINAL, LIVER, EFFUSION AND RENAL SAFETY CHARACTERIZATION IN THE BFORE TRIAL

Cortes JE



Bosutinib

P719

EFFICACY AND SAFETY OF BOSUTINIB IN LATER-LINE PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A SUB-ANALYSIS FROM THE PHASE 4 BYOND TRIAL

Gambacorti-Passerini C



Elranatamab

P897

UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Dalovisio A



Elranatamab

P949

A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3

Lesokhin AM



Inotuzumab Ozogamicin

P1736

CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

Russell-Smith A

Presented as ePoster

Publication Only

TTI-622

PB1820

CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML

Daver NG

Trial-In-Progress

Elranatamab

PB2032

MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Fonseca R

Trial-In-Progress



The compilation of presentations is for educational purposes only. You are entering a medical section of the Pfizer Landing Page. All materials here are presented for purposes of scientific exchange. They are NOT presented for any promotional purpose. All copyrights protected by law. Solely for non-commercial use.

© Pfizer Inc. All rights reserved.